Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study

Hayashi, T; Yamashita, T; Terashima, T; Suda, T; Okada, H; Asahina, Y; Hayashi, T; Hara, Y; Nio, K; Sunagozaka, H; Takatori, H; Arai, K; Sakai, Y; Yamashita, T; Mizukoshi, E; Honda, M; Kaneko, S

Yamashita, T (reprint author), Kanazawa Univ, Grad Sch Med Sci, Dept Gastroenterol, 13-1 Takara Machi, Kanazawa, Ishikawa 9208641, Japan.; Yamashita, T (reprint author), Kanazawa Univ, Kanazawa Univ Hosp, Grad Sch Med Sci, Dept Gen Med,Dept Syst Biol, 13-

BMC CANCER, 2017; 17 ( ):

Abstract

Background: Sorafenib is a multiple receptor tyrosine kinase inhibitor known to prolong overall survival in patients with advanced hepatocellular carc......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索